Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patientsfor Non Small Cell Lung CancerDrug: OsimertinibSites in Glenview, Park Ridge +144 more locationsSponsor: PrECOG, LLC.Sex: All·Age: 18+Code: NCT06538038·Recruiting·Listed Aug 2024Apply to this trial
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancerfor Anatomic Stage I Breast Cancer AJCC v8Sites in Glenview, Park Ridge +913 more locationsSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT05929768·Phase 3·Recruiting·Listed Jul 2023Apply to this trial
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumorsfor Metastatic Malignant Neoplasm in the LiverSites in Glenview, Lake Forest +378 more locationsSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT05040360·Phase 2·Recruiting·Listed Sep 2021Apply to this trial
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Bodyfor Castration-Resistant Prostate CarcinomaSites in Glenview, Lake Forest +172 more locationsSponsor: SWOG Cancer Research NetworkSex: Male·Age: 18+Code: NCT06470243·Phase 3·Recruiting·Listed Jun 2024Apply to this trial
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatinfor Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Sites in Glenview, Lake Forest +61 more locationsSponsor: NRG OncologySex: All·Age: 18+Code: NCT07441681·Phase 3·Recruiting·Listed Mar 2026Apply to this trial
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcomafor Endometrial CarcinomaSites in Glenview, Highland Park +329 more locationsSponsor: National Cancer Institute (NCI)Sex: Female·Age: 18+Code: NCT05256225·Phase 3·Recruiting·Listed Feb 2022Apply to this trial